12月5日至6日，2025心血管健康大会在北京国家会议中心隆重举行，大会吸引近2万人参会，来自国内外的心血管领域权威专家与学者，围绕守护民众心 血管健康展开深度交流。会上，津药达仁堂参与的国家科技重大专项——"速效救心丸治疗气滞血瘀型择期PCI相关冠脉微血管疾病的多中心随机对照研 究"重磅启动。 国家中医药管理局科技司相关负责人、中国科学院陈可冀院士、中国工程院张伯礼院士、复旦大学附属中山医院葛均波院士、北京中医药大学东直门医院 王勇院长、王显教授、北京大学第一医院霍勇教授、北京大学韩晶岩教授、河南中医药大学第一附属医院朱明军教授等多位专家、领导出席，52万人次线 上同步观看，共同见证这一重要时刻。 直击临床困境，破解心肌灌注"最后一公里"难题。冠状动脉微血管疾病是当前冠心病治疗的关键难点。数据显示，即使通过PCI手术成功开通堵塞的大血 管，仍有超过30%的患者因微循环障碍导致心肌组织灌注不足，严重影响术后恢复和生活质量。以心脑血管病为主的四大慢病重大专项是落实《"健康中 国2030"规划纲要》的重要举措。在葛均波院士引领下、霍勇教授、王显教授、朱明军教授、毛静远教授等诸多心血管领域专家共同努力，深耕冠状动脉 ...

中融亚太：洞察行业投资机会 在全球经济格局深度调整与技术革新加速演进的当下，市场环境正经历着前所未有的变革。中融亚太凭借对宏观趋势的敏锐捕捉与产业生态的深度解构，始 终致力于在复杂变局中发掘具有长期价值的投资赛道。通过整合全球资源与本土化运营经验，这家机构正以独特的视角审视不同行业的成长逻辑，为资本与 产业的高效对接搭建桥梁。 新能源领域的结构性机遇持续释放。随着全球碳中和目标的推进，光伏、储能与新能源汽车产业链展现出强劲的增长韧性。中融亚太观察到，光伏行业的技 术迭代正从追求转换效率向降低度电成本演进，钙钛矿电池的商业化突破或将重塑行业竞争格局。储能领域则呈现出技术路线多元化发展态势，液流电池在 长时储能场景的应用潜力与钠离子电池在资源约束下的替代价值，正吸引资本的密切关注。新能源汽车产业链的价值重心，正从整车制造向智能化零部件与 车规级芯片转移，软件定义汽车的时代已然开启。 在复杂多变的市场环境中，中融亚太始终坚持以深度研究为基础，以产业洞察为导向，在变革中把握机遇，在创新中创造价值。通过精准把握行业发展趋 势，深入理解企业成长逻辑，这家机构正与全球投资者共同探索可持续增长的投资路径，为推动产业升级与经济 ...

Core Viewpoint - The collaboration between Chongqing Medical University Second Affiliated Hospital and Taiji Group marks a significant step in the integration of government, medical, and enterprise sectors to modernize and industrialize traditional Chinese medicine [1][3]. Group 1: Collaboration and Objectives - The partnership aims to implement the "Healthy China" strategy and promote the revitalization of traditional Chinese medicine through the integration of clinical research capabilities and industry advantages [3]. - The focus is on creating an efficient transformation pathway from "classic prescriptions" to "modern products," enhancing the quality of the health industry in Chongqing [3][4]. Group 2: Institutional Strengths - Chongqing Medical University Second Affiliated Hospital has a strong foundation in clinical and research capabilities in traditional Chinese medicine, supported by its integrated medical center and key laboratories [3]. - The hospital has developed a closed-loop research and development system that addresses clinical needs, research breakthroughs, and result transformations [3]. Group 3: Strategic Goals - The collaboration aims to standardize and upgrade traditional Chinese medicine products, ensuring that scientifically validated and effective innovations benefit public health [3][4]. - Taiji Group emphasizes its commitment to merging traditional Chinese medicine with modern health lifestyles, focusing on making traditional formulations more convenient and accessible [4]. Group 4: Research and Development Center - A "Joint Research and Transformation Center for Traditional Chinese Medicine Formulations" will be established to focus on innovation in formulation processes, quality standards, clinical efficacy evaluation, and product development [4]. - The center aims to create a replicable and promotable model for collaborative innovation in the production, study, and application of traditional Chinese medicine [4]. Group 5: Public Engagement and Future Plans - The event included a public engagement component, allowing citizens to experience traditional Chinese medicine and receive health consultations from experts [4]. - The Chongqing Health Commission plans to continue optimizing the policy environment to support such collaborations, aiming to enhance public health and develop the local health industry [4].

Core Insights - Dong-E E-Jiao Co., Ltd. has been designated as a strategic partner by the Shandong Sports Bureau, providing comprehensive support to the Shandong delegation during the 15th National Games [1][2] - The company’s three core products—Dong-E E-Jiao, Compound E-Jiao Syrup, and Peach Blossom E-Jiao Cake—were awarded the title of "Designated Products for the Shandong Sports Delegation" [1][2] - Dong-E E-Jiao emphasizes its commitment to supporting local sports development as part of its corporate social responsibility, aligning its growth with regional sports initiatives [1] Company Initiatives - During the current National Games cycle, Dong-E E-Jiao has focused on enhancing its research system, product quality management, and supply chain capabilities to support sports initiatives [2] - The inclusion of its three core products in the designated product matrix reflects the company's comprehensive strength in quality systems, standard management, and supply chain capabilities [2] - Dong-E E-Jiao aims to continue integrating traditional Chinese medicine with modern sports health, driving innovation and expanding its collaboration with the sports health system [2]

Core Viewpoint - The restructuring of the "National Key Laboratory of Traditional Chinese Medicine Quality" into the "National Key Laboratory of Traditional Chinese Medicine Mechanism and Quality" signifies a strategic shift towards understanding the scientific mechanisms behind traditional Chinese medicine (TCM), particularly its immune regulation capabilities [1][2][3]. Group 1: Research Focus and Direction - The laboratory's new focus on "mechanism" indicates a transition from traditional empirical validation to modern mechanistic explanations, aiming to clarify how TCM works scientifically [3]. - The primary research direction will be the immune regulation mechanisms of TCM, with an ambition to lead global research in this area within 3 to 5 years [2][3]. - The laboratory aims to establish scientific evidence for the mechanisms of TCM, which is essential for quality control and ensuring clinical efficacy and safety [3]. Group 2: Development and Innovation in Macau - Macau's TCM industry is still developing, with a focus on innovative TCM research rather than traditional manufacturing [4]. - The laboratory has multiple research centers that support the development of TCM in Macau, including a center focused on classic formulations expected to enter the market within one to two years [4]. - The establishment of a drug regulatory science research center at the University of Macau will provide quality inspection services for both TCM and Western medicine [4]. Group 3: Talent Recruitment and International Collaboration - The laboratory plans to recruit talent with a background in TCM from developed countries, emphasizing the importance of international scientific education and achievements [7][8]. - There is an openness to non-Chinese scientists joining the team, which is expected to enhance the modernization and internationalization of TCM [7][8]. - The laboratory aims to create an internationalized work environment to attract global talent while also nurturing local talent from Macau [8][9].

中国发展网讯 记者明慧报道 11月15日上午，由中国当代医药杂志社和二十一世纪公益基金会主办，蒙 牛集团、扬子江药业集团、北京本草方源药业集团、百芝堂中医药集团、北京四方中药饮片有限公司等 单位协办，北京市大兴区卫生健康委员会、北京新融公益基金会等单位支持的第六届院士院长大会（简 称"两院论坛"）在北京市大兴区举行。中国中医药信息学会第四届理事会会长、国家中医药管理局原副 局长吴刚，中国科学院院士韩济生、陈润生、赵宇亮（线上），中国工程院院士蒋建东，第十三届全国 政协常委、国际核能院院士张勤，北京市大兴区委卫生健康工委书记、区卫生健康委主任牛祥君等来自 医药卫生界的行业领导、专家学者和来自全国各地的医疗机构负责人等320多位代表出席了15日上午举 行的开幕式。 开幕式由国家中医药管理局国际司原司长、中国医院协会副会长、中国中医科学院广安门医院原书记王 笑频主持，吴刚致辞。 在开幕式上，牛祥君在致辞中表示："今天我们有幸迎来医药健康领域的学术脊梁——各位院士，临床 实践一线的中坚力量——各位院长，以及深耕科研与产业赛道的专家、学者、企业家同仁。对大兴而 言，这既是一份至高荣誉，更是推动大兴卫生健康事业和医药健康 ...

Core Insights - The 2025 China Biotechnology Innovation Conference opened in Chengdu High-tech Zone, gathering over 1,000 experts and representatives from more than 50 well-known pharmaceutical companies to discuss the future of the global health industry [1][3] Event Overview - The conference, hosted by the China Biotechnology Development Center and organized by the Chengdu High-tech Zone Management Committee, spans three days and includes an opening ceremony, 14 sessions of sub-forums, technology achievement roadshows, and closed-door meetings [3] - The event features a comprehensive presentation of the latest dynamics, core challenges, and development opportunities in global biotechnology innovation through various formats [3] Key Reports and Presentations - The "2024 China Biopharmaceutical Park Competitiveness Ranking" was unveiled during the opening ceremony, with Chengdu High-tech Zone maintaining a leading position [3][5] - Notable presentations included: - A report by Academician Cao Xuetao on the strategic planning for innovative drug development over the next decade and the new era of biopharmaceuticals [3] - A report by Academician Chen Kaixian analyzing the development trends and innovation strategies in the chemical drug sector [4] - A report by Academician Chen Shilin discussing technological breakthroughs in the full industry chain development of traditional Chinese medicine [4] Specialized Sessions - The conference includes 14 specialized sessions covering topics such as AI-enabled innovative drug development, gene and cell therapy, modernization of traditional Chinese medicine, advanced industrial biotechnology, and disruptive technologies [4] Industry Reports - Four authoritative reports were released, including the "2025 China Life Sciences and Biotechnology Development Report" and the "2025 China Clinical Research Development Report," providing critical insights for industry development [5] - The "2025 China Biopharmaceutical Park Development Status Analysis Report" highlighted the competitive advantages of cities in biotechnology, with Chengdu High-tech Zone ranking alongside other leading innovation districts [5] New Initiatives - The "Global New Drug Discovery Center" was officially launched, aiming to integrate resources from over 3,000 biopharmaceutical companies in the region to create a comprehensive service system for drug discovery [6] - Chengdu High-tech Zone is focused on building a robust biopharmaceutical innovation ecosystem, enhancing collaboration between government, industry, academia, and research institutions to drive technological breakthroughs [6]

Core Viewpoint - The "Multi-target Cell Membrane Chromatography Intelligent Screening Analyzer" project, developed by Chengdu University of Traditional Chinese Medicine, Xi'an Jiaotong University, and Haineng Future Technology Group Co., Ltd., has been evaluated as a significant technological achievement that fills an international gap in the field [2][3][8]. Group 1: Project Evaluation - The evaluation was organized by the Sichuan Provincial Association for Science and Technology, with a panel of experts including academicians from various prestigious institutions [5][6]. - The expert panel unanimously agreed that the instrument is an international original, with advanced and reliable overall performance, and is a significant technological achievement [8]. Group 2: Instrument Features and Innovations - The instrument addresses the long-standing separation of "physical properties" and "activity" in traditional Chinese medicine research, providing critical support for establishing a research paradigm that aligns with the characteristics of traditional Chinese medicine [10]. - It is capable of accurately capturing key active components in complex systems, showcasing professional quality in its design, and has significant export potential and market appeal [10]. Group 3: Broader Implications - The achievement provides key technological support for explaining the scientific basis of traditional Chinese medicine compound preparations as innovative drugs, responding to major national regulatory needs [10]. - The project focuses on the collaborative action mechanism of "multi-component-multi-target" in traditional Chinese medicine, marking a significant leap towards intelligent analysis in the study of complex systems [12]. Group 4: Future Prospects - The instrument has vast application prospects not only in traditional Chinese medicine but also in natural product screening, drug development, quality control, and environmental testing [10]. - The successful development of the "Multi-target Cell Membrane Chromatography Intelligent Screening Analyzer" signifies a new phase in the intelligent analysis of complex systems, providing a robust technical support platform for modernizing traditional Chinese medicine and discovering innovative drugs [12][13].

Core Insights - The company Pianzaihuang has been awarded the "Most Investment Value Listed Company" at the 2025 Global Business Report Economic Forum, highlighting its long-term development potential recognized by the capital market [1] Group 1: Company Performance - Pianzaihuang has demonstrated excellence in corporate governance, value creation, strategic foresight, and social responsibility, which contributed to its recognition as a leading investment value company [1] - The company has a strong core product, Pianzaihuang, which has won the "West Pharmaceutical Gold Award" for liver and gallbladder medications, proving its effectiveness in preventing and treating acute and chronic liver damage [2] - Pianzaihuang's brand value has reached 43.739 billion yuan, ranking first in the "Hurun Brand List" for healthcare brands and leading the Chinese time-honored brand list [2] Group 2: Market Position and Strategy - The company has consistently ranked at the top of various industry lists, including the top 50 Chinese medicine companies and the top 100 pharmaceutical companies by main business income [2] - Pianzaihuang maintains a commitment to transparent operations and investor relations, having previously won the "Investor Relations Management Shareholder Return Award" [3] - The company aims to deepen the integration of production, education, and research, while exploring global market opportunities to enhance shareholder value and contribute to the modernization and internationalization of traditional Chinese medicine [3]

Core Points - The implementation of the "Private Economy Promotion Law" on May 20, 2025, is a significant milestone for the development of private enterprises in China, providing strong legal support for high-quality development in the private economy [1] - The law encourages private economic organizations to actively participate in technological innovation and the construction of a modern industrial system, which aligns with the goals of traditional Chinese medicine (TCM) enterprises [3][4] Company Insights - Fu Wang Guo Yi Tang, founded by Tang Huitian, is committed to continuous exploration in technological innovation, exemplified by their unique "Chinese Medicine Surgical Knife" system that aims to replace surgical interventions with specific herbal combinations [3][4] - The company emphasizes efficacy over excessive medical treatment and integrates traditional theories with modern pathology, addressing the talent bottleneck by collaborating with universities to train qualified TCM practitioners [4] - Fu Wang Guo Yi Tang has developed a series of health products focusing on "food and medicine homology," utilizing local medicinal materials while enhancing their health benefits [4] Industry Trends - The TCM industry is entering a golden era of high-quality development, driven by the "Healthy China 2030" initiative and advancements in digital technology [3] - Recent government policies, including the State Council's opinions on improving TCM quality, provide a clear development blueprint for the industry, with the "Private Economy Promotion Law" offering new opportunities and requirements for private enterprises [4][5] - The future of the TCM industry lies in leveraging modern technology to empower traditional wisdom, with Fu Wang Guo Yi Tang planning to enhance online sales channels and expand its reach through e-commerce partnerships [5]